Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Shoucheng Ning"'
Autor:
Jan Scicinski, George Fisher, Corey Carter, Cheryl Cho-Phan, Pamela Kunz, Shoucheng Ning, Susan Knox, Bryan Oronsky, Scott Caroen, Christopher Parker, Gary Fanger, Tony Reid
Publikováno v:
Redox Biology, Vol 5, Iss , Pp 422- (2015)
Background: RRx-001 is a novel NO and hypoxia mediated anticancer agent with epigenetic activity. In the first-in-human, Phase I trial, 5/5 patients who progressed on RRx-001 treatment were resensitized to previously refractory therapy, hinting at a
Externí odkaz:
https://doaj.org/article/ac42b765458d4bcfa7e40cd1563e5a81
Autor:
Jing Chen, Laurent A. Bekale, Shoucheng Ning, Kelly Khomtchouk, Susan J. Knox, Anping Xia, Zhixin Cao, Peter L. Santa Maria
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Oral mucositis refers to lesions of the oral mucosa observed in patients with cancer being treated with radiation with or without chemotherapy, and can significantly affect quality of life. There is a large unmet medical need to prevent oral mucositi
Autor:
Hongjuan Zhao1, Shoucheng Ning2, Rosalie Nolley1, Jan Scicinski3, Oronsky, Bryan3, Knox, Susan J.2, Peehl, Donna M.1 dpeehl@stanford.edu
Publikováno v:
Clinical Epigenetics. 1/19/2017, Vol. 9, p1-11. 11p.
Autor:
Shoucheng Ning, Pedro Cabrales, Susan J. Knox, Bryan Oronsky, Mark D. Bednarski, Jan Scicinski, Arnold L. Oronsky, Donna M. Peehl
Publikováno v:
Investigational new drugs, vol 34, iss 3
Investigational New Drugs
Investigational New Drugs
SummaryThe ‘holy grail’ in radiation oncology is to improve the outcome of radiation therapy (RT) with a radiosensitizer—a systemic chemical/biochemical agent that additively or synergistically sensitizes tumor cells to radiation in the absence
Publikováno v:
Oncotarget
// Hongjuan Zhao 1 , Shoucheng Ning 2 , Jan Scicinski 3 , Bryan Oronsky 3 , Susan J. Knox 2 and Donna M. Peehl 1 1 Department of Urology, Stanford University School of Medicine, Stanford, CA, USA 2 Department of Radiation Oncology, Stanford Universit
Autor:
Bryan Oronsky, Gary Fanger, Susan J. Knox, Donna M. Peehl, Jan Scicinski, Michelle M. Kim, Shoucheng Ning, Peter Langecker
Publikováno v:
Redox Biology
The endogenous mediator of vasodilation, nitric oxide (NO), has been shown to be a potent radiosensitizer. However, the underlying mode of action for its role as a radiosensitizer – while not entirely understood – is believed to arise from increa
Autor:
Scott Caroen, George A. Fisher, Jan Scicinski, Keola Beale, Chan Clayton, Huy V. Nguyen, Cheryl D. Cho-Phan, Gary R. Fanger, Jennifer Carney, Chris Parker, Meaghan Stirn, Tony R. Reid, Susan J. Knox, Bryan Oronsky, Shoucheng Ning
Publikováno v:
Cancer Research. 75:A1-35
Background: RRx-001 is a novel systemically non-toxic pan-epigenetic modulator of DNA methyltransferases, Histone Deacetylases, and lysine demethylases with broad activity both preclinically and clinically. In the first-in-man Phase I trial, five pat
Autor:
Yi-Bing Ouyang, Bruce M. MacIver, John R. Adler, Susan J. Knox, Shoucheng Ning, Rona G. Giffard
Publikováno v:
Cureus
The effects of high dose gamma radiation on brain tissue are poorly understood, with both limited and major changes reported. The present study compared the effects of gamma irradiation on the expression of interneuron markers within the hippocampal
Autor:
Donna M. Peehl, Jan Scicinski, Bryan Oronsky, Rosalie Nolley, Hongjuan Zhao, Shoucheng Ning, Susan J. Knox
Publikováno v:
Clinical Epigenetics
Background RRx-001, a dinitroazetidine derivative, is a novel anticancer agent currently in phase II clinical trials. It mediates immunomodulatory effects either directly through polarization of tumor associated macrophages or indirectly through vasc
Autor:
Arnold L. Oronsky, Nacer Abrouk, Donna M. Peehl, Jane B. Trepel, Kira Foygel, Jan Scicinski, Bryan Oronsky, Corey A. Carter, William L. Fitch, Pedro Cabrales, Hongjuan Zhao, Santosh Kesari, Min-Jung Lee, Tony R. Reid, Susan J. Knox, Carolyn M. Ray, Regina M. Day, Shoucheng Ning, Michelle M. Kim, Ramasamy Paulmurugan, Thomas A. Summers
Publikováno v:
Expert opinion on investigational drugs, vol 26, iss 1
Oronsky, B; Paulmurugan, R; Foygel, K; Scicinski, J; Knox, SJ; Peehl, D; et al.(2017). RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opinion on Investigational Drugs, 26(1), 109-119. doi: 10.1080/13543784.2017.1268600. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/9c1501w2
Oronsky, B; Paulmurugan, R; Foygel, K; Scicinski, J; Knox, SJ; Peehl, D; et al.(2017). RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opinion on Investigational Drugs, 26(1), 109-119. doi: 10.1080/13543784.2017.1268600. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/9c1501w2
© 2016 Informa UK Limited, trading as Taylor & Francis Group. Introduction: According to Hanahan and Weinberg, cancer manifests as six essential physiologic hallmarks: (1) self-sufficiency in growth signals, (2) insensitivity to growth-inhibitory si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dca7b04d469bcced5e4d092f188c206b
https://escholarship.org/uc/item/9c1501w2
https://escholarship.org/uc/item/9c1501w2